BeiGene Ltd ADR buy stratec
Zusammenfassung
Diese Einschätzung wurde am 05.02.19 mit einem Endkurs von 118,40 € beendet. Mit einer Rendite von 28,50 % entwickelte sich die Einschätzung BUY ganz nach Plan. stratec hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| BeiGene Ltd ADR | 16,15 % | 16,15 % | -33,77 % | -41,02 % |
| iShares Core DAX® | -0,92 % | -1,08 % | 12,16 % | 16,80 % |
| iShares Nasdaq 100 | 0,37 % | -0,56 % | 38,62 % | 49,37 % |
| iShares Nikkei 225® | 2,22 % | -2,83 % | 19,01 % | 4,64 % |
| iShares S&P 500 | -0,03 % | -0,79 % | 28,48 % | 42,48 % |
Kommentare von stratec zu dieser Einschätzung
In der Diskussion Beigene Ltd ADR diskutieren
stratec stimmt der Buy-Einschätzung von marge zu
stratec stimmt am 12.01.2018 der Buy-Einschätzung von marge aber mit dem Kursziel 130$ zu.
Überschrift: BeiGene is a Buy, as the stock is currently over 25% off its high!
News: MRTX and BGNE announced a licensing agreement for the MRTX receptor tyrosine kinase inhibitor sitravatinib in the Pacific region. Under the terms of this licensing agreement, BGNE paid MRTX $10 million upfront and "significant royalties" from the sales of any marketed product, as well as up to $123 million in other potential milestones.
Looking forward: This news is important for a number of reasons. First, drugs like sitravatinib are likely about to become a big deal in lung cancer, as science gets a better handle on rare oncogenes like mutant c-Met. For investors, these targeted agents are quite off the radar, and companies are going to capitalize in a big . Second, it further establishes BGNE as an important mediator between US and Pacific pharma. In addition, the cash infusion for MRTX is nothing scoff at, as their burn rate is quite high.
BeiGene launches late-stage study of tislelizumab in liver cancer. Dosing is underway in a Phase 3 clinical trial assessing BeiGene's tislelizumab in treatment-naive patients with advanced hepatocellular
carcinoma (liver cancer), the fourth indication being evaluated for the PD-1 inhibitor (Hodgkin lymphoma, non-small cell lung cancer, urothelial cancer).
The company is collaborating with Celgene on developing tislelizumab for solid tumors outside of Asia (except Japan).
Beendete Einschätzungen von stratec zu BeiGene Ltd ADR
BeiGene Ltd ADR
05.02.19
04.11.21
05.11.21
